EGFR, MUC1: Bispecific CAR-T Cell constructs (chimeric antigen receptors) that Recognize EGFR and MUC1 for the Treatment of Lung Cancer

FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE

Contact

Haskell Adler PhD MBA CLP
Senior Licensing Manager
Registered Patent Agent
Haskell.Adler@Moffitt.org
(813) 745-6596

19MA033N